Curis, Inc. announced a net loss of $8.1 million for Q3 2026 but highlighted progress in its emavusertib drug trials for chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL). The company is enrolling patients in two ongoing studies combining emavusertib with BTK inhibitors, showing promising early response rates, especially in BTK-naïve patients. Curis completed funding rounds extending its cash runway into early 2027 and plans to use trial data to support regulatory approval. Despite no revenue this quarter due to prior royalty sales, Curis remains focused on advancing emavusertib's development.
Curis' Q3 2026 business update provides context for health sector trading on Pluang. As of Nov 13, 2026 04:11 WIB, out of 150 priced health-sector US stocks, 23 rose and 124 fell. Among notable movers, CTXR gained 11.19% with predominantly sell orders (84% Sell / 16% Buy) and a typical hold time of 19 days, contrasting with SANA which dropped 11.79% but saw more buy interest (40% Sell / 60% Buy) and a longer hold time of 26 days.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
